Camrelizumab by Jiangsu Hengrui Medicine for Solid Tumor: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 19, 2023
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Camrelizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
Let's personalize your content